The Executive Team at Immuron is made up of extraordinarily talented individuals who bring to the company years of experience in their respective fields and have proven expertise in building innovative pipelines. Our team’s experience spans the full spectrum of discovery, clinical, regulatory and commercial with a strong track record in execution. We are focused on capitalizing on the programs we prioritize and to bringing life saving medicines to those patients who suffer from the diseases we target.
Dr Gary Jacob
Chief Executive Officer
Dr. Gary S. Jacob, Ph.D., has been Chief Executive Officer of Immuron Limited since November 16, 2018. Dr. Jacob has over 30 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research and development, operations, business development and capital financing.
He is the co-founder and founding CEO of Synergy Pharmaceuticals which went public in 2008, and is the co-inventor of TRULANCE® (plecanatide), an FDA approved drug which was approved in January 2017 to treat chronic GI disorders. From the founding of Synergy in 2008 as a public company until the FDA approval of TRULANCE® in 2017, Dr. Jacob raised over $500 million USD of capital in the public markets.
Dr. Jacob holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison and a BS in Chemistry from the University of Missouri-Columbia.
Chief Operating Officer
Dr Jerry Kanellos has over twenty years’ experience in the pharmaceutical and biotechnology industry, and has held leadership roles in business development, project management, intellectual property portfolio management research and development and senior management, and holds a PhD in medicine from the University of Melbourne.
Dr Kanellos spent five years with TransBio Limited where as Chief Operating Officer, he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along with development, management and maintenance responsibility for the intellectual property portfolio, research and development and technology transfer.
Prior to this, Dr Kanellos worked for five years as a consultant to the biotech industry and has provided development and commercialisation strategies for various bodies including academic institutes, private and publicly listed companies and government departments. He has also been involved in the establishment and management of several startup biotechnology companies.
During his ten years tenure in research and development at CSL Limited, Dr Kanellos gained considerable experience in the drug development process, formulation development through to pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls (CMC) programs for the approval, manufacture and launch of several products.
Director of US Sales
Travis is an accomplished, motivated leader with progressive years of proven success in dramatically increasing revenues and expanding market shares, while building key relationships. Building and leading top performing sales teams that embrace the highest standards of customer relationship management and retention. Excels at interacting with broad populations including senior management, staff, manufacturers, distributors, clinical professionals at physician practices, hospitals, government accounts, such as the VA, National and Regional accounts, clinics and universities. Effectively defines, develops and implements targeted action plans to maximize productivity, efficiency and profitability. Highly versatile; quickly masters new roles, responsibilities, technologies, and environments. Reputation for integrity, problem solving abilities, work ethic, and analytical skills.
Ms. Tobis joined Immuron with 8 years of project management experience regarding multi-national clinical studies in diverse therapeutic areas including Gastroenterology, Diabetes Mellitus, Oncology, Haematology, Cardiology, Neurology and Dermatology. During that time period she managed projects for leading major pharmaceutical companies, including Pfizer, Novartis, Roche, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer and Ingelheim.
Ms. Tobis expertise lies with the clinical operational as well as regulatory aspects of the clinical trials, from mega clinical trials recruiting thousands of patients, to small niche projects including highly selective protocols of only a few dozen.
In her last position she spent 5 years in the global CRO Company - PPD ltd, as Lead CRA responsible for multi-national teams within multiple clinical studies.
Ms. Tobis holds Bio-Medical MBA from the Business school of the College of Management Academic Studies in Rishon LeZion and a Bachelor of Science degree in Biotechnology from the Tel Aviv University.
Manufacturing Quality Director
Mr Moussakhani MEng. (CP), Grad. Cert. (Eng Mgt), BSc. (Chemistry), Dip. Bus. (FM), is a professional operations and production manager with over 25 years experience in the implementation of project, quality and process improvements in the manufacture of therapeutics. He has effectively managed all aspects of goods manufacturing practice production and worked with companies such as Hospira, Sigma Pharmaceuticals, Ensign Laboratories and Quantum.
Company Secretary & Chief Financial Officer
Phillip Hains is a Chartered Accountant and specialist in the public company environment who has served the needs of a number of public company boards of directors and related committees. He has over two decades of experience in providing accounting, administration, compliance and general management services. Holding a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants, Mr Hains is currently a Non-Executive Director of Savcor Limited (ASX:SAV) and of Non-For-Profit organisation Outward Bound Australia.